From preeclampsia to renal disease: A role of angiogenic factors and the renin-angiotensin aldosterone system?

Nephrology Dialysis Transplantation

Volumn 27, Issue SUPPL. 3, 2012, Pages

  Van Der Graaf, Anne Marijn ^a   Toering, Tsjitske J ^a   Faas, Marijke M ^a   Titia Lely, A ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

angiogenic factors; chronic kidney disease; hypertension; microalbuminuria; preeclampsia; renal haemodynamics; renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE; ANGIOGENIC FACTOR; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; RENIN; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; HIGH SODIUM INTAKE; HORMONE ACTION; HUMAN; INFANT MORTALITY; KIDNEY FAILURE; KIDNEY FUNCTION; MATERNAL HYPERTENSION; MATERNAL MORBIDITY; MATERNAL MORTALITY; MICROALBUMINURIA; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOGENESIS INDUCING AGENTS; FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 84868554368     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs278     Document Type: Review

References (62)

1. Maynard SE, Min J-Y, Merchan J et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658.
2. Noori M, Donald AE, Angelakopoulou A et al. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Circulation 2010; 122: 478-487.
3. Venkatesha S, Toporsian M, Lam C et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12: 642-649.
4. Cornelis T, Odutayo A, Keunen J et al. The kidney in normal pregnancy and preeclampsia. Semin Nephrol 2011; 31: 4-14.
5. Brown MA, Lindheimer MD, de Swiet M et al. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the study of hypertension in pregnancy (ISSHP). Hypertens Pregnancy 2001; 20: IX-XIV.
6. Anon. ACOG Practice Bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 2002; 99: 159-167.
7. Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 2011; 123: 2856-2869.
8. Salafia CM, Pezzullo JC, López-Zeno JA et al. Placental pathologic features of preterm preeclampsia. Am J Obstet Gynecol 1995; 173: 1097-1105.
9. Zhou Y, Damsky CH, Chiu K et al. Preeclampsia is associated with abnormal expression of adhesion molecules by invasive cytotrophoblasts. J Clin Invest 1993; 91: 950-960.
10. Lafayette RA, Druzin M, Sibley R et al. Nature of glomerular dysfunction in pre-eclampsia1. Kidney Int 1998; 54: 1240-1249.
11. Hennessy A, Makris A. Preeclamptic nephropathy. Nephrology 2011; 16: 134-143.
12. Strevens H, Wide-Swensson D, Hansen A et al. Glomerular endotheliosis in normal pregnancy and pre-eclampsia. BJOG 2003; 110: 831-836.
13. Garovic VD, Wagner SJ, Turner ST et al. Urinary podocyte excretion as a marker for preeclampsia. Am J Obstet Gynecol 2007; 196: 320.e1-320.e7.
14. Henao DE, Mathieson PW, Saleem MA et al. A novel renal perspective of preeclampsia: a look from the podocyte. Nephrol Dial Transplant 2007; 22: 1477.
15. Lu F, Longo M, Tamayo E et al. The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am J Obstet Gynecol 2007; 196: 396.e1-396.e7; discussion 396.e7.
16. Sison K, Eremina V, Baelde H et al. Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol 2010; 21: 1691-1701.
17. Veron D, Reidy KJ, Bertuccio C et al. Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease. Kidney Int 2010; 77: 989-999.
18. Benjamin N, Rymer J, Todd SD et al. Sensitivity to angiotensin II of forearm resistance vessels in pregnancy. Br J Clin Pharmacol 1991; 32: 523-525.
19. Gant NF, Daley GL, Chand S et al. A study of angiotensin II pressor response throughout primigravid pregnancy. J Clin Invest 1973; 52: 2682-2689.
20. Sanchez-Ramos L, Briones DK, Kaunitz AM et al. Prevention of pregnancy-induced hypertension by calcium supplementation in angiotensin II-sensitive patients. Obstet Gynecol 1994; 84: 349-353.
21. Herse F, Dechend R, Harsem NK et al. Dysregulation of the circulating and tissue-based renin-angiotensin system in preeclampsia. Hypertension 2007; 49: 604-611.
22. Merrill DC, Karoly M, Chen K et al. Angiotensin-(1-7) in normal and preeclamptic pregnancy. Endocrine 2002; 18: 239-246.
23. Dechend R, Homuth V, Wallukat G et al. AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation 2000; 101: 2382-2387.
24. Wenzel K, Rajakumar A, Haase H et al. Angiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats. Hypertension 2011; 58: 77-84.
25. Zhou CC, Zhang Y, Irani RA et al. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med 2008; 14: 855-862.
26. Walther T, Wallukat G, Jank A et al. Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature. Hypertension 2005; 46: 1275-1279.
27. Stepan H, Walther T. Questionable role of the angiotensin II receptor subtype 1 autoantibody in the pathogenesis of preeclampsia. Hypertension 2007; 50: e3; author reply e4.
28. Zhou CC, Ahmad S, Mi T et al. Angiotensin II induces soluble fmslike tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy. Circ. Res 2007; 100: 88-95.
29. Kim NH, Oh JH, Seo JA et al. Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney Int 2005; 67: 167-177.
30. Zhou CC, Ahmad S, Mi T et al. Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling. Hypertension 2008; 51: 1010-1019.
31. Siddiqui AH, Irani RA, Zhang Y et al. Recombinant vascular endothelial growth factor 121 attenuates autoantibody-induced features of pre-eclampsia in pregnant mice. Am J Hypertens 2011; 24: 606-612.
32. Verlohren S, Niehoff M, Hering L et al. Uterine vascular function in a transgenic preeclampsia rat model. Hypertension 2008; 51: 547-553.
33. Herse F, Verlohren S, Wenzel K et al. Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. Hypertension 2009; 53: 393-398.
34. Stepan H, Faber R, Wessel N et al. Relation between circulating angiotensin II type 1 receptor agonistic autoantibodies and soluble fms-like tyrosine kinase 1 in the pathogenesis of preeclampsia. J Clin Endocrinol Metab 2006; 91: 2424-2427.
35. Siddiqui AH, Irani RA, Blackwell SC et al. Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia. Hypertension 2010; 55: 386-393.
36. Bellamy L, Casas J-P, Hingorani AD et al. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 2007; 335: 974.
37. Smith GC, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129 290 births. Lancet 2001; 357: 2002-2006.
38. McDonald SD, Malinowski A, Zhou Q et al. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J 2008; 156: 918-930.
39. Zech PY, Colon S, Deteix P et al. Distant evolution of kidney arteriolar lesions and hypertension after pregnancy toxemia. Nephron 1980; 26: 296-300.
40. Vikse BE, Irgens LM, Bostad L et al. Adverse perinatal outcome and later kidney biopsy in the mother. J Am Soc Nephrol 2006; 17: 837-845.
41. Vikse BE, Irgens LM, Leivestad T et al. Preeclampsia and the risk of end-stage renal disease. N Engl J Med 2008; 359: 800-809.
42. McDonald SD, Han Z, Walsh MWet al. Kidney disease after preeclampsia: a systematic review and meta-analysis. Am J Kidney Dis 2010; 55: 1026-1039.
43. Gordin D, Hiilesmaa V, Fagerudd J et al. Pre-eclampsia but not pregnancy-induced hypertension is a risk factor for diabetic nephropathy in type 1 diabetic women. Diabetologia 2007; 50: 516-522.
44. van Beek E, Ekhart TH, Schiffers PM et al. Persistent abnormalities in plasma volume and renal hemodynamics in patients with a history of preeclampsia. Am J Obstet Gynecol 1998; 179: 690-696.
45. Spaan JJ, Ekhart T, Spaanderman MEA et al. Remote hemodynamics and renal function in formerly preeclamptic women. Obstet Gynecol 2009; 113: 853-859.
46. Saxena AR, Karumanchi SA, Brown NJ et al. Increased sensitivity to angiotensin II is present postpartum in women with a history of hypertensive pregnancy. Hypertension 2010; 55: 1239-1245.
47. Spaanderman MEA, Ekhart THA, de Leeuw PW et al. Angiotensin II sensitivity in nonpregnant formerly preeclamptic women and healthy parous controls. J Soc Gynecol Investig 2004; 11: 416-422.
48. Hladunewich MA, Kingdom J, Odutayo A et al. Postpartum assessment of the renin angiotensin system in women with previous severe, early-onset preeclampsia. J Clin Endocrinol Metab 2011; 96: 3517-3524.
49. Spaanderman ME, Ekhart TH, van Eyck J et al. Latent hemodynamic abnormalities in symptom-free women with a history of preeclampsia. Am J Obstet Gynecol 2000; 182: 101-107.
50. Chidambaram M, Duncan JA, Lai VS et al. Variation in the renin angiotensin system throughout the normal menstrual cycle. J Am Soc Nephrol 2002; 13: 446-452.
51. Hubel CA, Wallukat G, Wolf M et al. Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia. Hypertension 2007; 49: 612-617.
52. Spaanderman M, Ekhart T, van Eyck J et al. Preeclampsia and maladaptation to pregnancy: a role for atrial natriuretic peptide? Kidney Int 2001; 60: 1397-1406.
53. Hladunewich M, Karumanchi SA, Lafayette R. Pathophysiology of the clinical manifestations of preeclampsia. Clin J Am Soc Nephrol 2007; 2: 543-549.
54. Wolf M, Hubel CA, Lam C et al. Preeclampsia and future cardiovascular disease: potential role of altered angiogenesis and insulin resistance. J Clin Endocrinol Metab 2004; 89: 6239-6243.
55. Wikström A-K, Larsson A, Eriksson UJ et al. Early postpartum changes in circulating pro-and anti-angiogenic factors in early-onset and late-onset pre-eclampsia. Acta Obstet Gynecol Scand 2008; 87: 146-153.
56. Rajakumar A, Michael HM, Rajakumar PA et al. Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. Placenta 2005; 26: 563-573.
57. Di Marco GS, Reuter S, Hillebrand U et al. The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD. J Am Soc Nephrol 2009; 20: 2235-2245.
58. Germain AM, Romanik MC, Guerra I et al. Endothelial dysfunction: a link among preeclampsia, recurrent pregnancy loss, and future cardiovascular events? Hypertension 2007; 49: 90-95.
59. Yinon Y, Kingdom JCP, Odutayo A et al. Vascular dysfunction in women with a history of preeclampsia and intrauterine growth restriction: insights into future vascular risk. Circulation 2010; 122: 1846-1853.
60. Romundstad PR, Magnussen EB, Smith GD et al. Hypertension in pregnancy and later cardiovascular risk: common antecedents? Circulation 2010; 122: 579-584.
61. Sattar N, Greer IA. Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening? BMJ 2002; 325: 157-160.
62. Blaauw J, Graaff R, van Pampus MG et al. Abnormal endotheliumdependent microvascular reactivity in recently preeclamptic women. Obstet Gynecol 2005; 105: 626-632.